Plasma exchange as treatment for acute fatty liver disease of pregnancy

Mohammed Aabdi | Yassine Mellagui | Jamal Ouachaou | Essad Ounci | Houssam Bkiyar | Brahim Housni

Department of Anesthesiology and Intensive Care Unit, Faculty of Medicine and Pharmacy of Oujda, Mohammed VI University Hospital, Mohammed I University, Oujda, Morocco

Correspondence
Aabdi Mohammed, Department of Anesthesiology-Intensive Care Unit, Faculty of Medicine and Pharmacy of Oujda, Mohammed VI University Hospital, Mohammed I University, Oujda, Morocco. Email: med.aabdi@gmail.com

1 INTRODUCTION

Acute fatty liver diseases of pregnancy AFLP is a rare life-threatening situation for both mother and fetus with serious complications. In this paper, we represent a clinical case of a 27 years pregnant woman with AFLP and the management required plasma exchange with clinical and biological improvement.

AFLP is an obstetrical, life-threatening emergency, with complications for both mother and fetus that might include death.1-3 The lethality of this disease is due to hepatic and renal impairment.4

The clinical and biological manifestations are nonspecific, which makes distinguishing AFLP from other liver diseases of pregnancy such as HELLP syndrome and preeclampsia a challenge for physicians.1

In this paper, we report a clinical case of AFLP occurring in the third trimester with hepatic and renal failure with necessary admission to the ICU and 5 sessions of plasma exchange treatment with clinical and biological improvement.

2 CASE PRESENTATION

A 27-year-old woman, primiparous, with no medical illness, was admitted to the emergency at the 33rd week of pregnancy for progressive asthenia and jaundice.

The physical examination found a conscious patient, and vital signs: blood pressure 125/80 mm Hg, pulse rate 124 beats/min, respiratory rate 15 cycles/min, and oxygen saturation 96% at room air. The abdominal examination showed no abnormalities.

The complete blood count was as followed: hemoglobin 10 g/dL, thrombocytopenia with a platelet count of 57000/mm³, hypoglycemia at 0.55 g/L, hyperbilirubinemia of 82 mg/dL with direct bilirubin of 69 mg/dL; hepatic cytology: ASAT and ALAT were 12-13 times greater than limit, respecti vely, creatinine 41 mg/L, prothrombin ratio 35% and hypoalbuminemia 24 g/l.

The liver ultrasound showed no obstruction in the biliary tract or thrombosis in the hepatic vein with normal liver size and no renal dilatation or obstruction (Figure 1).
The obstetrical ultrasonography detected no cardiac activity, so a decision of pregnancy interruption was made. The delivery was normal with no complications.

To rule out the differential diagnosis of hepatic failure, antibodies against Hepatitis A, B, C, and E, and VIG serology were negative.

Acute fatty liver disease of pregnancy was suspected, and the patient was admitted to the ICU where initial management based on fluid resuscitation by glucose 10% solution, and blood product transfusion was initiated. The patient kept worsening both clinically and biologically as follows: neurological deteriorating (GCS 10/15) with normal cerebral CT SCAN, thrombocytopenia of 15 000/mm³, so the decision of initiation plasma exchange was made 2 days after ICU admission.

The patient received 5 daily courses of plasma exchange: 2 L were removed and replaced with 1.5 L of plasma each session.

After the fifth session, the patient showed both clinical improvement and biological improvement: she was conscious, and she had platelets 98 000/mm³ with normal liver enzymes (Table 1 and 2). She was discharged on day 12.

3 │ DISCUSSION

AFLP is an obstetrical, life-threatening situation that occurs during the third trimester or immediate postpartum period. It is a rare disease of pregnancy. Several risk factors have been identified including multigravida state, male fetus, co-existing of other liver diseases, previous episodes of AFLP, and underweight mothers.

The pathophysiology of AFLP is associated with certain genetic impairments in mother and fetus such as long-chain 3-hydroxyacyl CoA dehydrogenase (LCHAD).

![Doppler ultrasound of the liver showing no thrombosis](image)

**FIGURE 1** Doppler ultrasound of the liver showing no thrombosis

| TABLE 1 Evolution of clinical signs |
|------------------------------------|
| **Clinical Case** | First day of plasma exchange | Last day of plasma exchange | Discharge |
| | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 12 |
| GCS | 15/15 | 10/15 | 10/15 | 11/15 | 12/15 | 12/15 | 13/15 | 15/15 |
| Jaundice | + | + | + | + | - | - | - | - |
| Abdominal pain | + | + | + | - | - | - | - | - |
| Vomiting | - | - | - | - | - | - | - | - |

*Note:* +, Present. -, Absent.

| TABLE 2 Evolution of biological Parameters |
|-------------------------------------------|
| **Parameters** | First day of plasma exchange | Last day of plasma exchange | Discharge |
| | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 12 |
| Hemoglobin g/dl | 10 | 9.3 | 9 | 9 | 8.5 | 8.7 | 9 | 9.3 |
| Platelet: unit/µm³ | 57 000 | 15 000 | 22 000 | 29 000 | 53 000 | 69 000 | 72 000 | 98 000 |
| Créatinine mg/l | 41 | 46 | 37 | 28 | 21 | 16 | 13 | 8 |
| Uréa | 1.5 | 2.1 | 2.0 | 1.6 | 1.2 | 0.7 | 0.6 | 0.3 |
| ASAT | 300 | 322 | 302 | 210 | 98 | 77 | 70 | 42 |
| ALAT | 325 | 317 | 310 | 215 | 102 | 79 | 69 | 45 |
| Prothrombin ratio | 35% | 22% | 37% | 45% | 51% | 62% | 69% | 85% |
AFLP is associated with a high risk of AFLP. FAOD are caused by a deficiency of enzymes involved in mitochondrial metabolism of fatty acid. Other fetal fatty acid oxidation defects reported being associated with AFLP such as SCAD (short-chain acyl CoA dehydrogenase), MCAD (Medium-chain acyl CoA dehydrogenase), and MTP (mitochondrial trifunctional protein). Clinical manifestations of AFLP are not specific and are similar to other liver diseases of pregnancy, they include nausea, vomiting, malaise, anorexia, abdominal pain, jaundice, polydipsia, polyuria encephalopathy, liver, and kidney failure. In our case, the patient presented asthenia, jaundice, liver and kidney failure, and later encephalopathy.

Laboratory tests reveal elevated serum bilirubin level, hypoglycemia, elevated transaminases and ammonia, kidney failure, coagulopathy, and metabolic acidosis. In our case, the patient had hypoglycemia, cytolysis, kidney, and liver failure.

The differential diagnosis of AFLP is other liver disorders of pregnancy such as HELLP syndrome, and preeclampsia. The Swansea criteria is a useful tool to help physicians to distinguish AFLP from other liver diseases of pregnancy. Baby delivery is the main treatment. Plasma exchange is an important tool that can help to improve the prognosis in the severe and complicated case.

Postpartum management is challenging, and special care should be taken to acute liver failure, renal impairment, and disseminated intravascular coagulation.

The management requires admission to ICU for monitoring for coagulopathy, massif blood transfusion, and correction of hypoglycemia, mechanical ventilation, dialysis, and plasmapheresis.

Plasma exchange is associated with improved clinical results including maternal mortality. The mechanism consists of removing endotoxins proteins, intravascular volume, support of coagulation factors, and acid-base balance, which leads to improvement of hepatic recovery, duration of hospitalization, and decrease in mortality.

The indication of plasma exchange in AFLP is reserved for advanced and complicated cases after the failure of other conventional intensive medical management.

Literature review founds that PE was an effective therapy for severe cases of AFLP: 50 of 53 patients recovered in one data, and 37 of 39 improved in another data.

4 | CONCLUSION

AFLP is a life-threatening situation for both mother and fetus. The diagnosis should be quick for proper management. The Swansea criteria help physicians to distinguish AFLP from other liver diseases of pregnancy. Baby delivery is the main treatment. Plasma exchange is an important tool that can help to improve the prognosis in the severe and complicated case.

ACKNOWLEDGMENTS

Published with written consent of the patient.

CONFLICT OF INTEREST

The authors do not declare any conflict of interest.

AUTHOR CONTRIBUTIONS

Dr Aabdi Mohammed: wrote the original draft, conceptualize the data, designed the methodology, involved in resources, conceptualized the data, designed the methodology, validated the data, and approved the version to be submitted. Dr Mellagui Yassine: wrote and edited the review, involved in formal analysis, visualized the data, supervised the data, investigated the data, and approved the version to be submitted. Dr Ouachaou Jamal: wrote and edit the review, involved in formal analysis, visualized the data, and approved the version to be submitted. Dr Es-Sad Ounci: visualized the data, wrote and edited the review, supervised the data, investigated the data, and approved the version to be submitted. Pr Bkiyar Houssam.: wrote and edited the review, visualized the data, approved the version to be submitted. Pr Housni: administered the project, visualized the data, wrote and edited the review, involved in resources, conceptualized the data, designed the methodology, validated the data, and approved the version to be submitted.

| TABLE 3 The Swansea criteria |
|-----------------------------|
| **Symptoms:**              |
| • Vomiting                  |
| • Abdominal pain            |
| • Polydipsia/polyuria       |
| • Encephalopathy            |
| **Laboratory:**             |
| • Leukocytosis              |
| • Hypoglycemia              |
| • Elevated urate            |
| • Elevated bilirubin        |
| • Elevated transaminases    |
| • Elevated ammonia          |
| • Coagulopathy              |
| • Renal impairment          |
| **Imaging pathology:**      |
| • Ascit/bright liver on ultrasound |
| • Microvesicular steatosis on liver biopsy |
submitted. All the authors have read and approved the final version of the manuscript.

**PATIENT’S PERSPECTIVE**

The patient expressed her satisfaction with the treatment.

**ETHICAL STATEMENT**

The study reflects the authors’ own research and analysis in a truthful and complete manner.

**DATA AVAILABILITY STATEMENT**

The data used to support the findings of this study are available from the corresponding author.

**ORCID**

Mohammed Aabdi https://orcid.org/0000-0003-2692-2225

Yassine Mellagui https://orcid.org/0000-0002-4785-5116

**REFERENCES**

1. Liu J, Ghaziani TT, Wolf JL. Acute fatty liver disease of pregnancy: updates in pathogenesis, diagnosis and management. *Am J Gastroenterol*. 2017;112:838-846.

2. Sheehan H. The pathology of acute yellow atrophy and delayed chloroform poisoning. *J Obstetrical Gynecol*. 1940;47:49-62.

3. Riely CA. Acute fatty liver of pregnancy. *Semin Liver Dis*. 1987;7:47-54.

4. Martin JN, Briery CM, Rose CH, Owens MT, Bofill JA, Files JC. Postpartum protein exchange as adjunctive therapy for severe acute fatty liver of pregnancy. *J Clin Apherisis*. 2008;23:138-143.

5. Peniche-Moguel KG, Sanchez-Diaz JS, Lopez-Guzman C, Calyeca-Sanchez MV, Castaneda-Valladares E. Plasmapheresis for acute liver failure in acute fatty liver of pregnancy. *Acta Colomb Cuid Intensivo*. 2017;173:222-225.

6. Westbrook RH, Dusheiko G, Williamson C. Pregnancy and liver disease. *J Hepatol*. 2016;64:933-945.

7. Italian Association for the study of the Liver AISF: AISF position paper on liver disease and pregnancy. *Dig Liver Dis*. 2016;48:120-137.

8. Allen AM, Kim WR, Larson JG, et al. The epidemiology of liver diseases unique to pregnancy in a US community: a population-based study. *Clin Gastroenterol HEPATOL*. 2016;14:287-294.

9. Homer L, Hebert T, Nousbaum J-B, et al. Comment faire le diagnostic de stéatohepatite aiguë gravidique en urgence? [how to confirm the presence of acute fatty liver of pregnancy in an emergency] *Gynecol Obstet Fert*. 2008;37:245-261.

10. Knight M, Nelson-Piercy C, Kurinczuk JJ, et al. A prospective national study of acute fatty liver of pregnancy in the UK. *Gut*. 2008;57:951-956.

11. Browning MF, Levy HL, Wilkins-Haug LE, et al. Fetal fatty acid oxidation defects and maternal liver disease in pregnancy. *Obstet Gynecol*. 2006;107:115-120.

12. de Nagy J, Strittmatter CA, Lee RV. Acute fatty liver of Pregnancy presenting as hepatic encephalopathy at 28 weeks gestation. *J Obstet Gynaecol Res*. 2008;28:100-102.

13. Vigil-De GP. Acute fatty liver and HELLP syndrome: two distinct pregnancy disorders. *Int J Gynaecol Obstet*. 2001;73:215-220.

14. Nelson DB, Yost NO, Cunningham FG. Acute fatty liver of pregnancy: Clinical outcomes and expected duration of recovery. *Am J Obstet Gynecol*. 2013;209(456):e1-7.

15. Joueidi Y, Peoc’h K, Lous le M, et al. Maternal and neonatal outcomes and prognostic factors in acute fatty liver of pregnancy. *Eur J Obstetric Gynecol Reprod Biol*. 2020;252:198-205.

16. Wei Q, Zhang L, Lui X. Clinical diagnosis and treatment of acute fatty liver of pregnancy: a literature review and 11 new cases. *J Gynaecol Res*. 2010;36:751-756.

17. Garcia V-D, Montufar-Rueda C. Acute fatty liver of pregnancy: diagnosis, treatment and outcome based on 35 consecutive cases. *J Matern-Fetal Neonatal Med*. 2011;24:1143-1146.

18. Naoum EE, Leffert LR, Chitilian HV, et al. Acute fatty liver of pregnancy: pathophysiology, Anesthetic implications and Obstetric management. The American Society of Anesthesiologists. *Anesthesiology*. 2019;130:446-461.

19. Burroughs AK, Seong NH, Dojcinov DM, Scheuer PJ, Sherlock SV. Idiopathic acute fatty liver of pregnancy in 12 patients. *Q J Med*. 1982;51:481-497.

20. Westbrook RH, Yecoman AD, Joshi D, et al. Outcomes of severe pregnancy-related liver disease: Refining the role of transplantation. *Am J Transplant*. 2010;10:2520-2526.

21. Mjahed K, Charra B, Hammoudi D, et al. Acute fatty liver of pregnancy. *Arch Gynecol obstet*. 2006;274:349-353.

22. Dwivedi S, Runmei M. Retrospective study of severe cases with acute fatty liver of pregnancy. *ISRN Obstet Gynecol*. 2013;82:457-460.

23. Ding J, Han LP, Lou XP, et al. Effectiveness of combining plasma exchange with plasma perfusion in acute fatty liver of pregnancy: A retrospective analysis. *Gynecol Obstet invest*. 2015;79:97-100.

24. Yu CB, Chen JJ, Du WB, et al. Effects of plasma exchange combined with continuous renal replacement therapy on acute fatty liver of pregnancy. *Hepatobiliary Pancreat Dis Int*. 2014;13:179-183.

25. Tang W, Huang Z, Wang Y, Bo H, Fu P. Effect of plasma exchange on hepatocyte oxidative stress, mitochondria function and apoptosis in patients with acute fatty liver of pregnancy. *Artif Organs*. 2012;36:E39-47.

26. Jin F, Cao Y, Zhang Y, Yang Y, Zhang B. Therapeutic effects of plasma exchange for the treatment of 39 patients with acute fatty liver of pregnancy. *Discover Med*. 2012;13(72):369-373.

27. Seyyed Majidi MR, Vafaeimanesh J. Plasmapheresis in acute fatty liver of pregnancy: an effective treatment. *Cas Rep Obstet Gynecol*. 2013;615975.

How to cite this article: Aabdi M, Mellagui Y, Ouachaaou J, Oun ci E, Bkiyar H, Housni B. Plasma exchange as treatment for acute fatty liver disease of pregnancy. *Clin Case Rep*. 2021;9:1594–1597. https://doi.org/10.1002/ccr3.3845